BRAF
Driver mutation in melanoma (50%), colorectal, thyroid, and lung cancers. BRAF V600E targeted by dabrafenib + trametinib and others.
No Clinical Trials found for this biomarker.
Driver mutation in melanoma (50%), colorectal, thyroid, and lung cancers. BRAF V600E targeted by dabrafenib + trametinib and others.
No Clinical Trials found for this biomarker.